Document is current
Any future updates will be listed below
-
Authors
Vanderbeke, Lore https://orcid.org/0000-0002-3364-1213
Janssen, Nico A. F. https://orcid.org/0000-0002-9629-8627
Bergmans, Dennis C. J. J. https://orcid.org/0000-0002-4224-6426
Bourgeois, Marc
Buil, Jochem B. https://orcid.org/0000-0003-4031-0778
Debaveye, Yves https://orcid.org/0000-0003-1784-8297
Depuydt, Pieter https://orcid.org/0000-0001-5164-5376
Feys, Simon https://orcid.org/0000-0002-7516-9471
Hermans, Greet https://orcid.org/0000-0001-5340-1500
Hoiting, Oscar
van der Hoven, Ben https://orcid.org/0000-0003-2225-4602
Jacobs, Cato
Lagrou, Katrien https://orcid.org/0000-0001-8668-1350
Lemiale, Virginie https://orcid.org/0000-0002-1736-747X
Lormans, Piet https://orcid.org/0000-0001-9978-1414
Maertens, Johan https://orcid.org/0000-0003-4257-5980
Meersseman, Philippe
Mégarbane, Bruno https://orcid.org/0000-0002-2522-2764
Nseir, Saad https://orcid.org/0000-0002-7618-0357
van Oers, Jos A. H. https://orcid.org/0000-0001-8666-9810
Reynders, Marijke https://orcid.org/0000-0003-2079-1279
Rijnders, Bart J. A. https://orcid.org/0000-0003-3343-9610
Schouten, Jeroen A. https://orcid.org/0000-0001-9118-4420
Spriet, Isabel https://orcid.org/0000-0001-6342-0676
Thevissen, Karin https://orcid.org/0000-0003-0275-9072
Thille, Arnaud W. https://orcid.org/0000-0002-7798-6715
Van Daele, Ruth https://orcid.org/0000-0002-8353-2103
van de Veerdonk, Frank L. https://orcid.org/0000-0002-1121-4894
Verweij, Paul E. https://orcid.org/0000-0002-8600-9860
Wilmer, Alexander https://orcid.org/0000-0002-4176-3608
Brüggemann, Roger J. M. https://orcid.org/0000-0002-7618-725X
Wauters, Joost https://orcid.org/0000-0002-5983-3897
,
Rijnders, Bart
Verweij, Paul
van de Veerdonk, Frank
Schauwvlieghe, Alexander
Wolfs, Tom
Wauters, Joost
Lagrou, Katrien
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03378479 at ClinicalTrials.govDocuments that mention this clinical trial
Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial
https://doi.org/10.1007/s00134-021-06431-0
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme
- License Information
-
More Information
Article History
Received: 8 March 2021
Accepted: 5 May 2021
First Online: 29 May 2021
Declarations
:
: JBB reports grants from F2G, grants from Gilead Sciences, grants from Thermo Fisher Scientific, outside the submitted work. KL received consultancy fees from MSD, SMB Laboratoires Brussels and Gilead, non-financial support from Pfizer and MSD, received speaker fees from Gilead Sciences, FUJIFILM WAKO and Pfizer and a grant from Thermo Fisher Scientific. VL reports financial support of Pfizer, Fisher Paykel, Gilead Sciences, Alexion and Celgene to her research group, outside the submitted work. JM reports grants, personal fees and non-financial support from Gilead Sciences, MSD and Pfizer; personal fees and non-financial support from Cidara, F2G and Mundipharma; outside the submitted work. AWT reports personal fees and non-financial support from Fisher&Paykel, outside the submitted work. RVD reports non-financial support from Pfizer and Gilead Sciences, outside the submitted work. LV reports non-financial support from Gilead Sciences, outside the submitted work. PEV reports grants from Mundipharma, grants from F2G, grants from Pfizer, grants from Thermofisher, grants from Gilead Sciences, non-financial support from IMMY, grants from Cidara, outside the submitted work. RJMB reports consultancy fees from Mundipharma, Cidara, Amplyx, F2G, Gilead, Pfizer and MSD, speaker fees from Pfizer and Gilead, grants from Pfizer, Gilead and MSD. JW received speakers fee from MSD, Pfizer and Gilead, consultancy fee from Gilead and he obtained investigator-initiated grants from Gilead, Pfizer and MSD.
: All study procedures were performed in compliance with the principles of the Declaration of Helsinki, the principles of good clinical practice and in accordance with all applicable regulatory requirements. The study protocol was approved by the ethical committee of all participating centers in Belgium and France, and by the independent ethical committee Arnhem-Nijmegen for all 5 participating Dutch sites (CMO 2018-4041).
: Written informed consent was obtained from all individual patients or their legal representative.
